Evidence map›Paper›PMID 32735605›Full record

ArticlePloS one2020

Immunodeficient mice are better for modeling the transfusion of human blood components than wild-type mice.

Sophia A Blessinger, Johnson Q Tran, Rachael P Jackman, Renata Gilfanova, Jacqueline Rittenhouse, Alan G Gutierrez, John W Heitman, Kelsey Hazegh, Tamir Kanias, Marcus O Muench

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. A Monocytic Barrier to the Humanization of Immunodeficient Mice.Current stem cell research & therapy · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sophia A BlessingerVitalant Research Institute, San Francisco, CA, United States of America.ORCID 0000-0001-5742-4144
Johnson Q TranVitalant Research Institute, San Francisco, CA, United States of America.ORCID 0000-0002-5263-6321
Rachael P JackmanVitalant Research Institute, San Francisco, CA, United States of America.ORCID 0000-0001-8591-7819
Renata GilfanovaVitalant Research Institute, San Francisco, CA, United States of America.
Jacqueline RittenhouseVitalant Research Institute, San Francisco, CA, United States of America.
Alan G GutierrezVitalant Research Institute, San Francisco, CA, United States of America.
John W HeitmanVitalant Research Institute, San Francisco, CA, United States of America.
Kelsey HazeghVitalant Research Institute, Denver, CO, United States of America.
Tamir KaniasVitalant Research Institute, Denver, CO, United States of America.
Marcus O MuenchVitalant Research Institute, San Francisco, CA, United States of America.ORCID 0000-0001-8946-6605
Vitalant · USUniversity of California, San Francisco · US

Funding

The impact of illness and medical treatments on the alloantibody response to platelet transfusionR01HL144501 · NHLBI · VITALANT · PI JACKMAN, RACHAEL PERETZ · 2019 to 2022
$3.0M
Effect of blood donor sex and testosterone on predisposition to hemolysis in stored red blood cellsR01HL134653 · NHLBI · VITALANT · PI KANIAS, TAMIR · 2018 to 2022
$1.9M
Mechanisms regulating alloimmunization and tolerance with pathogen reduction and transfusion of allogeneic plateletsR01HL133024 · NHLBI · VITALANT · PI JACKMAN, RACHAEL PERETZ · 2016 to 2018
$1.1M
NHLBI NIH HHS R01 HL133024NHLBI NIH HHS R01 HL134653NHLBI NIH HHS R01 HL144501
6 · The paper itself

Abstract

Animal models are vital to the study of transfusion and development of new blood products. Post-transfusion recovery of human blood components can be studied in mice, however, there is a need to identify strains that can best tolerate xenogeneic transfusions, as well as to optimize such protocols. Specifically, the importance of using immunodeficient mice, such as NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, to study human transfusion has been questioned. In this study, strains of wild-type and NSG mice were compared as hosts for human transfusions with outcomes quantified by flow cytometric analyses of CD235a+ erythrocytes, CD45+ leukocytes, and CD41+CD42b+ platelets. Complete blood counts were evaluated as well as serum cytokines by multiplexing methods. Circulating human blood cells were maintained better in NSG than in wild-type mice. Lethargy and hemoglobinuria were observed in the first hours in wild-type mice along with increased pro-inflammatory cytokines/chemokines such as monocyte chemoattractant protein-1, tumor necrosis factor α, keratinocyte-derived chemokine (KC or CXCL1), and interleukin-6, whereas NSG mice were less severely affected. Whole blood transfusion resulted in rapid sequestration and then release of human cells back into the circulation within several hours. This rebound effect diminished when only erythrocytes were transfused. Nonetheless, human erythrocytes were found in excess of mouse erythrocytes in the liver and lungs and had a shorter half-life in circulation. Variables affecting the outcomes of transfused erythrocytes were cell dose and mouse weight; recipient sex did not affect outcomes. The sensitivity and utility of this xenogeneic model were shown by measuring the effects of erythrocyte damage due to exposure to the oxidizer diamide on post-transfusion recovery. Overall, immunodeficient mice are superior models for xenotransfusion as they maintain improved post-transfusion recovery with negligible immune-associated side effects.

Indexed as

Models, AnimalAnimalsBlood Component TransfusionErythrocyte TransfusionHeterograftsHumansLeukocyte TransfusionMiceMice, Inbred NODMice, SCIDPlatelet Transfusion

Identifiers

PMID32735605
PMCPMC7394438
OpenAlexW3046269893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.